PL437896A1 - Way to determine the risk of cancer in men according to the concentration of arsenic in the blood - Google Patents

Way to determine the risk of cancer in men according to the concentration of arsenic in the blood

Info

Publication number
PL437896A1
PL437896A1 PL437896A PL43789621A PL437896A1 PL 437896 A1 PL437896 A1 PL 437896A1 PL 437896 A PL437896 A PL 437896A PL 43789621 A PL43789621 A PL 43789621A PL 437896 A1 PL437896 A1 PL 437896A1
Authority
PL
Poland
Prior art keywords
concentration
arsenic
blood
cancer
risk
Prior art date
Application number
PL437896A
Other languages
Polish (pl)
Other versions
PL243835B1 (en
Inventor
Jan LUBIŃSKI
Cezary Cybulski
Jacek Gronwald
Tomasz Huzarski
Róża Derkacz
Wojciech MARCINIAK
Anna Jakubowska
Original Assignee
Read-Gene Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Read-Gene Spółka Akcyjna filed Critical Read-Gene Spółka Akcyjna
Priority to PL437896A priority Critical patent/PL243835B1/en
Publication of PL437896A1 publication Critical patent/PL437896A1/en
Publication of PL243835B1 publication Critical patent/PL243835B1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób określenia ryzyka zachorowania na raka u mężczyzn, charakteryzujący się tym, że obejmuje ilościową ocenę stężenia arsenu we krwi osoby badanej, przy czym stężenie wskazuje na blisko 5 krotnie zmniejszone ryzyko zachorowania na raka w stosunku do podgrupy ze stężeniem arsenu we krwi < 0,7 µg/l lub > 1,14 µg/l, w przypadku występowania wartości stężenia arsenu we krwi w przedziale 0,7 - 1,14 µg/l.The subject of the application is a method of determining the risk of cancer in men, characterized by the fact that it includes a quantitative assessment of the concentration of arsenic in the blood of the test person, where the concentration indicates an almost 5-fold reduced risk of cancer in relation to the subgroup with the concentration of arsenic in the blood < 0.7 µg/l or > 1.14 µg/l if the concentration of arsenic in the blood is between 0.7 - 1.14 µg/l.

PL437896A 2021-05-19 2021-05-19 Method of determining the risk of cancer in men depending on the concentration of arsenic in the blood PL243835B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL437896A PL243835B1 (en) 2021-05-19 2021-05-19 Method of determining the risk of cancer in men depending on the concentration of arsenic in the blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL437896A PL243835B1 (en) 2021-05-19 2021-05-19 Method of determining the risk of cancer in men depending on the concentration of arsenic in the blood

Publications (2)

Publication Number Publication Date
PL437896A1 true PL437896A1 (en) 2022-11-21
PL243835B1 PL243835B1 (en) 2023-10-16

Family

ID=84191873

Family Applications (1)

Application Number Title Priority Date Filing Date
PL437896A PL243835B1 (en) 2021-05-19 2021-05-19 Method of determining the risk of cancer in men depending on the concentration of arsenic in the blood

Country Status (1)

Country Link
PL (1) PL243835B1 (en)

Also Published As

Publication number Publication date
PL243835B1 (en) 2023-10-16

Similar Documents

Publication Publication Date Title
CL2019002478A1 (en) Formulation of monoclonal anti-vrs.
DE60228557D1 (en) CANDIDA-PROOF
BRPI0812875A2 (en) &#34;METHOD TO IDENTIFY IF AN INDIVIDUAL IS AT RISK OF SEVERA SEPSIS DEVELOPMENT, SPECIFIC ANTIBODY FOR HEPARIN-BINDING PROTEIN, METHOD TO REDUCE THE RISK OF AN INDIVIDUAL SEVERA,&#34; SEVEN SEP.
MX2020010387A (en) Methods for detecting and quantifying fgf21.
CY1119797T1 (en) LACTOPHERINE FOR USE IN ALZHEIMER DIAGNOSIS AND PREDICTION
PL437046A1 (en) Serum arsenic, zinc and selenium concentration as a marker of survival in patients with prostate cancer in Poland
ZA202300353B (en) Lateral flow assay device for detection of analytes and method of detection thereof
PL437896A1 (en) Way to determine the risk of cancer in men according to the concentration of arsenic in the blood
BR112022012477A2 (en) ADJUSTMENT METHOD, MOBILE DEVICE, COMPUTER PROGRAM, COMPUTER READable STORAGE MEDIA AND KIT
PL437894A1 (en) Way to determine the risk of cancer in men according to the concentration of zinc in the blood
PL437898A1 (en) Way to determine the risk of cancer in men depending on the concentration of selenium in the blood
PL437899A1 (en) Way to determine the risk of cancer in men according to the concentration of lead in the blood
PL438655A1 (en) Method of determining the risk of cancer in women depending on concentration of lead in the blood
PL437895A1 (en) Way to determine the risk of cancer in men according to the concentration of copper in the blood
PL437897A1 (en) Way to determine the risk of cancer in men according to the concentration of cadmium in the blood
PL439315A1 (en) The method of determining the risk of cancer in women depending on the concentration of selenium in the blood
PL433150A1 (en) Method for determining the risk of cancers in women with BRCA1 mutations, depending on blood lead level
PL438038A1 (en) Method of determining risk of cancer in women depending on age, history of smoking and selenium concentration in the blood
PL439313A1 (en) Method for determining the risk of cancers in women, depending on concentration of arsenic in the blood
PL437608A1 (en) Method of determining the risk of cancer in women according to the concentration of cadmium in the blood
PL446712A1 (en) Correlation between serum selenium and zinc concentrations as a prognostic marker in patients with prostate cancer
PL438040A1 (en) Serum manganese concentration as a prognostic marker in patients with breast cancer
PL438563A1 (en) Serum selenium concentration as a marker of survival in patients with malignant melanoma in Poland
PL439314A1 (en) Method for determining the risk of cancers in women, depending on concentration of cadmium in the blood
PL414266A1 (en) Concentration of selenium in blood as a risk factor for cancers in women